Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone172

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone93

Views

Views
July 202520
August 20251
September 20251
October 20252
November 20255
December 202524
January 202640
Download CSV file
 untranslated
 untranslated

Top country views

Views
Finland60
United States12
Brazil8
United Kingdom4
Kenya2
Argentina1
Ecuador1
France1
Ireland1
Mexico1
 

Top cities views

Views
Helsinki60
São Paulo2
Albuquerque1
Ambato1
Atakum1
Cantagalo1
Cape Town1
Dallas1
Dublin1
Huntingdon1